21:13 , May 16, 2019 |  BC Extra  |  Company News

May 16 Company Quick Takes: Iconic oncology deals; plus Zymeworks-GSK, Aimmune and more

Iconic in pair of deals to develop lead oncology program  Iconic Therapeutics Inc. (South San Francisco, Calif.) granted Exelixis Inc. (NASDAQ:EXEL) an option to license ICON-2 for $7.5 million up front and funding for preclinical...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
07:00 , Apr 19, 2004 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Targacept Inc. Winston-Salem, N.C. Technology: Neuronal nicotinic receptor (NNR) chemistry and biology Disease focus: Neurology Clinical status: Phase II Founded: 2000 as a spinout from R.J. Reynolds Tobacco Co. University collaborators: Wake Forest University School...
08:00 , Mar 29, 2004 |  BioCentury  |  Strategy

All that Jazz . . .

All that Jazz . . . Company Raised Date Focus Investors Jazz $250.0 3/24/04 Neurology, cancer, endocrine Kohlberg Kravis Roberts; Prospect Venture Partners; Versant Ventures; Beecken Petty O'Keefe; Golden Gate Capital; Thoma Cressey Equity Partners;...
08:00 , Mar 24, 2003 |  BioCentury  |  Finance

Ebb & Flow

Echoing a trend seen on the company side, banks both big and small continue to search for the headcount sweetspot in the midst of the bear market. Last week's choppers included merchant banker Thomas Weisel...
08:00 , Mar 19, 2003 |  BC Extra  |  Financial News

Targacept raises additional $14 million

Targacept (Winston-Salem, N.C.) raised an additional $14 million to close its second round financing, bringing the total raised in the round to $60 million. The lead investor was Nomura International. Other investors included Oxford Bioscience...